Brower Piven Announces An Investigation Of The Acquisition Of Genoptix, Inc. By Novartis AG
The law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Genoptix, Inc. (“Genoptix”) (NASDAQ:GXDX) and other violations of state law by the Board of Directors of Genoptix relating to the proposed acquisition of the company by Novartis AG (“Novartis”). The firm’s investigation seeks to determine whether Genoptix and its Board breached their fiduciary duties by failing to maximize shareholder value.
On January 24, 2011, Genoptix announced that it had entered into a definitive merger agreement to be acquired by Novartis in a transaction valued at approximately $470 million. Under the terms of the agreement, Novartis will commence an all cash tender offer for all outstanding shares of common stock of Genoptix at $25.00 per share. Each of Genoptix’s directors and executive officers has already agreed to tender their shares in the offer. Although Novartis’s acquisition price represents a 39% premium over Genoptix’s share value on December 13, 2010, when rumors of a sale sparked a price surge, at least one securities analyst has set a price target of $28.00 per share, and Genoptix stock traded as high as $38.79 per share as recently as April 30, 2010.
If you currently own shares of Genoptix and would like to learn more
about the investigation being conducted by Brower Piven, you may e-mail
or call Brower Piven, who will, without obligation or cost to you,
attempt to answer your questions. You may contact Brower Piven by email
by calling 410/415-6616, or at Brower Piven, A Professional Corporation,
1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower
Piven have combined experience litigating securities and other class
action cases of over 60 years.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV